Wakix is an anti-narcoleptic drug owned by Harmony. The medicine contains pitolisant hydrochloride as an active ingredient. Wakix received market authorization on 14 August, 2019 and it is available in an oral tablet dosage form.
The generic version of Wakix is expected to be available from 07 March, 2030, following the expiry of the last patent. From 15 August, 2023, drug patent challenges can be filed against Wakix.
Wakix, with its active ingredient pitolisant hydrochloride, is effectively used in the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.
Wakix holds 3 drug patents that cover a range of uses, with no patents expired to date. The last patent of Wakix is expected to expire on 07 March, 2030. Below are the details of the patent: